Grandeur Peak Global Advisors LLC Purchases Shares of 19,340 STAAR Surgical (NASDAQ:STAA)

Grandeur Peak Global Advisors LLC purchased a new stake in STAAR Surgical (NASDAQ:STAA - Free Report) during the fourth quarter, according to the company in its most recent filing with the SEC. The firm purchased 19,340 shares of the medical instruments supplier's stock, valued at approximately $470,000.

Several other institutional investors also recently made changes to their positions in STAA. KLP Kapitalforvaltning AS acquired a new position in STAAR Surgical in the fourth quarter valued at $180,000. FMR LLC raised its holdings in STAAR Surgical by 79.3% in the third quarter. FMR LLC now owns 7,092 shares of the medical instruments supplier's stock valued at $263,000 after buying an additional 3,136 shares during the period. Quantbot Technologies LP acquired a new position in STAAR Surgical during the fourth quarter valued at approximately $278,000. Y Intercept Hong Kong Ltd purchased a new stake in STAAR Surgical during the fourth quarter worth approximately $292,000. Finally, Counterpoint Mutual Funds LLC acquired a new stake in shares of STAAR Surgical in the fourth quarter worth $298,000. 96.70% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at STAAR Surgical

In related news, major shareholder Broadwood Partners, L.P. acquired 8,200 shares of STAAR Surgical stock in a transaction that occurred on Wednesday, April 9th. The stock was acquired at an average price of $15.08 per share, for a total transaction of $123,656.00. Following the transaction, the insider now directly owns 13,518,591 shares of the company's stock, valued at $203,860,352.28. This trade represents a 0.06 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In the last three months, insiders have acquired 1,742,581 shares of company stock worth $28,407,543. 1.00% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several research analysts have commented on the company. Jefferies Financial Group lowered STAAR Surgical from a "buy" rating to a "hold" rating in a research report on Wednesday, February 12th. Stifel Nicolaus decreased their price target on STAAR Surgical from $38.00 to $20.00 and set a "buy" rating for the company in a report on Wednesday, February 12th. William Blair cut shares of STAAR Surgical from an "outperform" rating to a "market perform" rating in a research report on Wednesday, February 12th. BTIG Research downgraded shares of STAAR Surgical from a "buy" rating to a "neutral" rating in a research note on Wednesday, February 12th. Finally, Mizuho downgraded STAAR Surgical from an "outperform" rating to a "neutral" rating and lowered their target price for the company from $45.00 to $17.00 in a research note on Wednesday, February 12th. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and one has assigned a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $25.29.

STAAR Surgical Price Performance

STAA traded up $0.75 during trading hours on Friday, hitting $16.89. 485,153 shares of the stock were exchanged, compared to its average volume of 791,123. STAAR Surgical has a 12 month low of $13.50 and a 12 month high of $49.86. The stock has a 50-day simple moving average of $17.17 and a 200-day simple moving average of $23.55. The stock has a market cap of $833.10 million, a price-to-earnings ratio of -41.20 and a beta of 0.75.

STAAR Surgical Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.